Athira Pharma Rebrands to LeonaBio, Secures $90 Million Financing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Globenewswire
- Company Rebranding: Athira Pharma has rebranded to LeonaBio, reflecting its commitment to developing innovative therapies for metastatic breast cancer, marking the beginning of a strategic transformation.
- Financing Support: The company secured $90 million through a private placement, which is expected to support the development of its new drug lasofoxifene and help achieve key clinical and regulatory milestones by 2028.
- Clinical Trial Progress: The ongoing ELAINE-3 trial for lasofoxifene is over 50% enrolled, with data expected in mid-2027, potentially providing new treatment options for metastatic breast cancer patients.
- Drug Potential: Lasofoxifene is a novel selective estrogen receptor modulator designed to target metastatic breast cancer patients who have developed resistance to endocrine therapy, filling a significant gap in current treatment options and holding substantial market potential.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
